Cargando…

KRAS K104 modification affects the KRAS(G12D)-GEF interaction and mediates cell growth and motility

Mutant RAS genes play an important role in regulating tumors through lysine residue 104 to impair GEF-induced nucleotide exchange, but the regulatory role of KRAS K104 modification on the KRAS(G12D) mutant remains unclear. Therefore, we simulated the acetylation site on the KRAS(G12D) three-dimensio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chih-Chieh, Hsu, Chia-Yi, Lin, Hsiao-Yun, Zeng, Hong-Qi, Cheng, Kuang-Hung, Wu, Chia-Wei, Tsai, Eing-Mei, Hsieh, Tsung-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567070/ https://www.ncbi.nlm.nih.gov/pubmed/33060649 http://dx.doi.org/10.1038/s41598-020-74463-5

Ejemplares similares

Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer
por: Weng, Ching-Chieh, et al.
Publicado: (2019)

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
por: Fakih, Marwan, et al.
Publicado: (2022)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

KRAS Ubiquitination at Lysine 104 Retains Exchange Factor Regulation by Dynamically Modulating the Conformation of the Interface
por: Yin, Guowei, et al.
Publicado: (2020)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway
por: Yang, Qing, et al.
Publicado: (2019)

PPDPF Promotes the Development of Mutant KRAS‐Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1
por: Ni, Qian‐Zhi, et al.
Publicado: (2022)

Cten Is Targeted by Kras Signalling to Regulate Cell Motility in the Colon and Pancreas
por: Al-Ghamdi, Saleh, et al.
Publicado: (2011)

A Novel KRAS Antibody Highlights a Regulation Mechanism of Post-Translational Modifications of KRAS during Tumorigenesis
por: Assi, Mohamad, et al.
Publicado: (2020)

Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis
por: Weng, Ching-Chieh, et al.
Publicado: (2018)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation
por: Huang, Chi-Jung, et al.
Publicado: (2016)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

Landscape of KRAS(G12C), Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
por: Salem, Mohamed E., et al.
Publicado: (2022)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Let-7g Upregulation Attenuated the KRAS–PI3K–Rac1–Akt Axis-Mediated Bioenergetic Functions
por: Hung, Kuang-Chen, et al.
Publicado: (2023)

The Inhibition of Wnt Restrain KRAS(G12V)-Driven Metastasis in Non-Small-Cell Lung Cancer
por: Hung, Pei-Shan, et al.
Publicado: (2020)

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
por: Vaclova, Tereza, et al.
Publicado: (2022)

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS(G12C) inhibitors
por: Feng, Siyu, et al.
Publicado: (2022)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

An integrated model for predicting KRAS dependency
por: Tsai, Yihsuan S., et al.
Publicado: (2023)

Quo vadis, Kras?
por: Schneider, Günter, et al.
Publicado: (2013)

KRAS: Druggable at Last
por: Herzberg, Benjamin O, et al.
Publicado: (2023)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
por: Tsai, Yihsuan S., et al.
Publicado: (2022)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma
por: Chang, Kuang-Leei, et al.
Publicado: (2016)

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023)

Venetoclax Decreases the Expression of the Spike Protein through Amino Acids Q493 and S494 in SARS-CoV-2
por: Chen, Chih-Chieh, et al.
Publicado: (2022)

Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver-only and lung-only metastases
por: Chuang, Shih-Chang, et al.
Publicado: (2020)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8dri8l84it4cuk1d1aefif7bjp